Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 130

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 130
---
 predict treatment outcomes for  
 LB-102 amongst identified patient populations and achieve clinical success; |

| • |     | the timing of and costs involved in obtaining and maintaining regulatory approval of LB-102 and any future product candidates that we may identify or develop; |

| • |     | the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of LB-102; |

| • |     | our ability to efficiently and cost-effectively conduct our current and future clinical trials; |

| • |     | our ability to obtain funding for our operations necessary to complete further development and commercialization 
 of LB-102, if approved;                                                                                          |

| • |     | our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements, 
 including our ability to comply with our financial obligations pursuant to the terms of such agreements;         |

| • |     | the timing and likelihood of the achievement of milestones pursuant to our existing collaboration and licensing 
 agreements;                                                                                                     |

| • |     | our ability to identify and develop LB-102 for treatment of additional 
 indications;                                                           |

| • |     | the performance of our third-party service providers, including our suppliers and manufacturers; |

| • |     | the rate and degree of market acceptance and clinical utility for LB-102 
 and any other product candidates we may develop;                         |

| • |     | the effects of competition with respect to LB-102 or any of our future                        
 product candidates, as well as innovations by current and future competitors in our industry; |

| • |     | our estimates regarding the potential market opportunities and the number of patients for LB-102 and any future product candidates, if approved for commercial use; |

| • |     | the implementation of our strategic plans for our business, LB-102, and 
 any future product candidates we may develop;                           |

| • |     | our intellectual property position, including the scope of protection we are able to establish, maintain, defend 
 and enforce for intellectual property rights covering LB-102 and any future product candidates we may develop;   |

82

| • |     | our ability to attract and retain key scientific or management personnel; |

| • |     | regulatory and legal developments in the United States and foreign countries; |

| • |     | our ability to attract and retain employees and collaborators with development, regulatory, and commercialization 
 expertise;                                                                                                        |

| • |     | our ability to comply with the terms of our term loan agreement and our